Dual promoters control expression of the Bacillus anthracis virulence factor AtxA.
ABSTRACT The AtxA virulence regulator of Bacillus anthracis is required for toxin and capsule gene expression. AtxA is a phosphotransferase system regulatory domain-containing protein whose activity is regulated by phosphorylation/dephosphorylation of conserved histidine residues. Here we report that transcription of the atxA gene occurs from two independent promoters, P1 (previously described by Dai et al. [Z. Dai, J. C. Sirard, M. Mock, and T. M. Koehler, Mol. Microbiol. 16:1171-1181, 1995]) and P2, whose transcription start sites are separated by 650 bp. Both promoters have -10 and -35 consensus sequences compatible with recognition by sigma(A)-containing RNA polymerase, and neither promoter depends on the sporulation sigma factor SigH. The dual promoter activity and the extended untranslated mRNA suggest that as-yet-unknown regulatory mechanisms may act on this region to influence the level of AtxA in the cell.
- SourceAvailable from: Andrei P Pomerantsev[Show abstract] [Hide abstract]
ABSTRACT: Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37[degree sign]C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer. This response requires the presence of the pXO1 virulence plasmid-encoded pleiotropic regulator AtxA. To better understand the genetic basis of this response, we utilized a controlled in vitro system and Next Generation sequencing to determine and compare RNA expression profiles of the parental strain and an isogenic AtxA-deficient strain in a 2 x 2 factorial design with growth environments containing or lacking carbon dioxide. We found 15 pXO1-encoded genes and 3 chromosomal genes that were strongly regulated by the separate or synergistic actions of AtxA and carbon dioxide. The majority of the regulated genes responded to both AtxA and carbon dioxide rather than to just one of these factors. Interestingly, we identified two previously unrecognized small RNAs that are highly expressed under physiological carbon dioxide concentrations in an AtxA-dependent manner. Expression levels of the two small RNAs were found to be higher than that of any other gene differentially expressed in response to these conditions. Secondary structure and small RNA-mRNA binding predictions for the two small RNAs suggest that they may perform important functions in regulating B. anthracis virulence. A majority of genes on the virulence plasmid pXO1 that are regulated by the presence of either CO2 or AtxA separately are also regulated synergistically in the presence of both. These results also elucidate novel pXO1-encoded small RNAs that are associated with virulence conditions.BMC Genomics 03/2014; 15(1):229. · 4.40 Impact Factor
- PLoS Pathogens 01/2010; 6(3). · 8.14 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Natamycin is an important polyene macrolide antifungal agent produced by several Streptomyces strains and is widely used as a food preservative and fungicide in food, medicinal and veterinary products. In order to increase the yield of natamycin, this study aimed at cloning and overexpressing a natamycin-positive regulator, slnM2, with different promoters in the newly isolated strain Streptomyces lydicus A02, which is capable of producing natamycin. The slnM gene in S. lydicus is highly similar to gene pimM (scnRII), the pathway-specific positive regulator of natamycin biosynthesis in S. natalensis and S. chattanoogensis, which are PAS-LuxR regulators. Three engineered strains of S. lydicus, AM01, AM02 and AM03, were generated by inserting an additional copy of slnM2 with an ermEp* promoter, inserting an additional copy of slnM2 with dual promoters, ermEp* and its own promoter, and inserting an additional copy of slnM2 with its own promoter, respectively. No obvious changes in growth were observed between the engineered and wild-type strains. However, natamycin production in the engineered strains was significantly enhanced, by 2.4-fold in strain AM01, 3.0-fold in strain AM02 and 1.9-fold in strain AM03 when compared to the strain A02 in YEME medium without sucrose. These results indicated that the ermEp* promoter was more active than the native promoter of slnM2. Overall, dual promoters displayed the highest transcription of biosynthetic genes and yield of natamycin.Journal of Industrial Microbiology 10/2013; · 1.80 Impact Factor
JOURNAL OF BACTERIOLOGY, Oct. 2008, p. 6483–6492
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Vol. 190, No. 19
Dual Promoters Control Expression of the Bacillus anthracis Virulence
Cristina Bongiorni,§ Tatsuya Fukushima, Adam C. Wilson, Christina Chiang, M. Cecilia Mansilla,¶
James A. Hoch, and Marta Perego*
Division of Cellular Biology, Department of Molecular and Experimental Medicine, The Scripps Research Institute,
10550 North Torrey Pines Road, La Jolla, California 92037
Received 29 May 2008/Accepted 18 July 2008
The AtxA virulence regulator of Bacillus anthracis is required for toxin and capsule gene expression. AtxA is
a phosphotransferase system regulatory domain-containing protein whose activity is regulated by phosphory-
lation/dephosphorylation of conserved histidine residues. Here we report that transcription of the atxA gene
occurs from two independent promoters, P1 (previously described by Dai et al. [Z. Dai, J. C. Sirard, M. Mock,
and T. M. Koehler, Mol. Microbiol. 16:1171–1181, 1995]) and P2, whose transcription start sites are separated
by 650 bp. Both promoters have ?10 and ?35 consensus sequences compatible with recognition by ?A-
containing RNA polymerase, and neither promoter depends on the sporulation sigma factor SigH. The dual
promoter activity and the extended untranslated mRNA suggest that as-yet-unknown regulatory mechanisms
may act on this region to influence the level of AtxA in the cell.
The virulence of Bacillus anthracis, the causative agent of
anthrax, results from the production of a tripartite toxin and an
antiphagocytic poly-D-glutamic acid capsule (21). The toxin
consists of three proteins: protective antigen (PA), encoded by
the pagA gene; edema factor, encoded by the cya gene; and
lethal factor, encoded by the lef gene. The pagA, cya, and lef
genes are located noncontiguously on the pXO1 virulence plas-
mid, and their expression requires the product of another plas-
mid gene, atxA (9, 17, 22, 32). The AtxA regulator is also
required for transcription of the capBCADE operon for cap-
sule production, which is located on the second virulence plas-
mid of B. anthracis, pXO2 (7, 12, 19, 33). The requirement for
AtxA for cap operon transcription is mediated by the products
of two pXO2 genes, acpA and acpB, which share some simi-
larity with AtxA (11).
In addition to being required for virulence gene expression,
AtxA has also been shown to be a global regulator of gene
expression in B. anthracis. Expression profiling indicated that
the transcription of a variety of genes, located either on the
AtxA belongs to the wide family of phosphotransferase sys-
tem regulatory domain (PRD)-containing proteins (31). PRDs
are structural domains generally found in RNA-binding anti-
terminators or in DNA-binding transcription factors. The ac-
tivity of PRD-containing proteins is generally regulated by
phosphorylation on conserved histidine residues. The phos-
phorylation is carried out by enzymes of the phosphoenolpyru-
vate:sugar phosphotransferase system (for a review, see refer-
ence 10). Phosphorylation of the His199 residue in PRD1 of
AtxA was shown to be necessary for its activity, while phos-
phorylation of His379 in PRD2 was inhibitory. This suggested
that regulation of virulence factor production in B. anthracis
may be linked to carbohydrate metabolism (31).
Virulence factor gene expression is also affected by growth
under specific conditions; capsule synthesis and toxin protein
synthesis are induced when strains are grown in defined media
with bicarbonate at elevated atmospheric CO2concentrations
(?5%). Although this induction requires AtxA, the transcrip-
tion of atxA itself did not appear to be affected by growth under
CO2/bicarbonate conditions compared to growth in air (8, 18).
The atxA gene was reported to be transcribed from a pro-
moter (referred to here as P1) (9) located 99 bp upstream from
the ATG translational start site (Fig. 1). The AbrB protein,
characterized in Bacillus subtilis as a transition state regulator
that suppresses postexponential-phase gene expression during
the exponential phase of growth, was shown to bind to the atxA
promoter region (30) and to repress its transcription (28). In
agreement with these results, deletion of the abrB gene in B.
anthracis resulted not only in elevated atxA expression in ex-
ponential phase but also in earlier transcription and higher
levels of transcription of pagA, cya, and lef compared to the
parental strain (28).
Deletion of sigH, encoding the sigma factor for sporulation
initiation in B. anthracis, was shown to result in a sporulation
defect and to completely inhibit atxA and toxin gene expres-
sion. However, Strauch et al. (30) observed that transcription
of the atxA P1 promoter did not require SigH when the B.
subtilis model system was used.
Here we report that transcription of atxA initiates at an
additional promoter (P2) located within the coding sequence
of a gene on pXO1, orf118 (referred to here as the pXO1-118
gene), which is upstream of and divergently transcribed from
* Corresponding author. Mailing address: Division of Cellular Biol-
ogy, Mail Code MEM-116, Department of Molecular and Experimen-
tal Medicine, The Scripps Research Institute, 10550 North Torrey
Pines Road, La Jolla, CA 92037. Phone: (858) 784-7912. Fax: (858)
784-7966. E-mail: email@example.com.
† Supplemental material for this article may be found at http://jb
‡ Manuscript 19413 from The Scripps Research Institute.
§ Present address: Genencor International, Inc.—A Danisco Divi-
sion, 925 Page Mill Rd., Palo Alto, CA 94304.
¶ Present address: Instituto de Biologia Molecular y Cellular de
Rosario, Suipacha 531, 2000 Rosario, Argentina.
?Published ahead of print on 1 August 2008.
the atxA gene. This study showed that, although the Orf118
protein was not required for atxA expression, its coding se-
quence contained promoter elements critical for full activation
of this gene. Furthermore, our analysis revealed that SigH is
not required for atxA transcription under either air or CO2/
bicarbonate growth conditions.
MATERIALS AND METHODS
Bacterial strains and growth conditions. B. anthracis strain 34F2 (pXO1?
pXO2?) was used throughout this study. Cells were grown in LB medium in air
or in R medium (27) in an atmosphere containing 5% CO2. Antibiotics were
added at the following concentrations: kanamycin, 7.5 ?g/ml; chloramphenicol,
7.5 ?g/ml; spectinomycin, 50 ?g/ml; erythromycin, 5 ?g/ml; and lincomycin, 25
?g/ml. Escherichia coli strains DH5? and TG1 were used for plasmid construc-
tion and propagation. E. coli strains C600 and SCS110 were used for the pro-
duction of unmethylated DNA for transformation in B. anthracis. Antibiotics
were used at the following concentrations: ampicillin, 100 ?g/ml; kanamycin, 30
?g/ml; and spectinomycin, 100 ?g/ml.
Electrocompetent cells of B. anthracis were prepared as described by Koehler
et al. (17).
Construction of pXO1-118, atxA, and sigH deletion strains. The sequences of
the oligonucleotide primers used in this study are shown in Table S1 in the
supplemental material. Plasmid pORICm carrying a temperature-sensitive rep-
lication origin and a chloramphenicol resistance marker was used for construc-
tion of the pXO1-118 gene deletion strain (5). A 720-bp fragment downstream of
the pXO1-118 gene was PCR amplified using oligonucleotides Delta 118Kpn and
Delta 118Bam and cloned in pORICm at the KpnI and BamHI sites. An 860-bp
fragment upstream of the pXO1-118 gene was also PCR amplified using oligo-
nucleotides Delta 118Sal and Delta 118Pst and cloned in the plasmid indicated
above at the SalI-PstI sites. Finally, a blunt-ended spectinomycin cassette (5) was
cloned at the HincII site located between the two cloned fragments in the vector
multiple cloning site. The resulting plasmid (pORICm-?118) was transformed
into strain 34F2 and used to generate a deletion-spectinomycin replacement of
the pXO1-118 gene essentially as described previously (5).
Plasmid pORICm was also used for construction of the atxA deletion strain. A
fragment containing the entire atxA coding region and approximately 500 bp
upstream was PCR amplified using oligonucleotide primers Ba118delta and
AtxA3?Bam and cloned in the EcoRI-BamHI sites of pORICm. The resulting
plasmid, after transformation in dam E. coli strain C600, was digested with BclI
and EcoRV, and the 670-bp excised fragment was replaced by the spectinomycin
cassette as a BamHI-HincII fragment. The resulting plasmid (pORI-?atxA) (Fig.
1) was used to transform strain 34F2 and generate a deletion replacement of the
atxA gene essentially as described previously (5).
A deletion in the sigH gene (BA0093 in the B. anthracis Ames strain; accession
number NC_003997) was generated by using the protocol of Janes and Stibitz
(16) and the temperature-sensitive plasmid pORICm-SceI (3). A 1,090-bp frag-
ment generated by PCR amplification using oligonucleotide primers Basig
HpEco and BasigH3?Bam2 and digested with BamHI was cloned in the HincII-
FIG. 1. pXO1-118-atxA region on the pXO1 virulence plasmid: restriction map of the pXO1 plasmid carrying the pXO1-118 and atxA genes
with the restriction sites relevant for this study. The open arrows indicate the direction of gene transcription. The fragments cloned in the plasmids
are indicated below the restriction map. The directions of transcription of the spectinomycin resistance cassette used for gene deletion are indicated
by arrowheads. The positions of the oligonucleotide primers used in the RT-PCR and primer extension reactions are indicated above the restriction
map. The designations of the primers are shortened for clarity.
6484BONGIORNI ET AL.J. BACTERIOL.
BamHI sites of pORICm-SceI. A spectinomycin cassette, purified as an EcoRV-
EcoRV fragment, was cloned in the pORICm-SceI-SigH plasmid digested with
BglII and treated with T4 DNA polymerase (New England Biolabs). The result-
ing plasmid, designated pORI-?SigH, generated a spectinomycin cassette inser-
tion in the sigH gene of strain 34F2, giving rise to strain 34F2?sigH.
Each mutant construct was verified by diagnostic PCR using genomic DNA.
All cloned fragments were fully sequenced to ensure the fidelity of the amplifi-
cation reaction. A diagnostic PCR was also carried out with genomic DNA using
atxA-specific primers to ensure that the pXO1 plasmid was not lost during the
Construction of lacZ fusion plasmids. The pTCVlac transcriptional fusion
vector was used for construction of the atxA-lacZ reporter plasmids (24). A map
of the cloned fragments is shown in Fig. 1. The fragment in pAtxA10 was
obtained by PCR amplification using oligonucleotide primers AtxA5?promEco
and AtxA3?Bam. The fragment was digested with EcoRI and EcoRV (the latter
naturally occurring within the atxA sequence), and the purified 200-bp fragment
was cloned in the EcoRI and SmaI sites of pTCVlac. Similarly, fragments in
pAtxA13, pAtxA15, and pAtxA12 were generated with oligonucleotide primers
Delta 118Eco2, Ba118delta, and AtxA5?upEcoRI, respectively, as the forward
primers and primer AtxA3?Bam as the reverse primer. The fragments were
digested with EcoRI and EcoRV and cloned in the EcoRI-SmaI-digested
pTCVlac vector. The fragment in pAtxA12 was also cloned in the pHT315 vector
digested with EcoRI and SmaI to generate pAtxA3 for in trans complementation.
The fragment in pAtxA19 was generated with oligonucleotide primers
AtxA5?upEcoRI and AtxApromBam2. The fragment was digested with EcoRI
and BamHI and cloned in similarly digested pTCVlac. Fragments in pAtxA20
and pAtxA21 were generated with oligonucleotides AtxA5?upEcoRI and
delta118Eco2, respectively, as the forward primers and AtxApromBam3 and
AtxApromBam2, respectively, as the reverse primers. The approximately 500-
and 200-bp digested fragments, respectively, were cloned in the EcoRI-BamHI-
digested pTCVlac vector.
Plasmid pAtxA18 was constructed in three steps. First, the product of PCR
amplification carried out with oligonucleotide primers AtxA5?upEcoRI and
1183?Kpn was cloned in the EcoRI-KpnI sites of the pUC19-derived multiple
cloning site of plasmid pHT315 (2). The resulting plasmid was digested with
KpnI and BamHI and ligated to the KpnI-BamHI-digested PCR product ob-
tained with oligonucleotide primers 1185?Kpn and AtxA3?Bam. The resulting
plasmid contained the entire pXO1 fragment shown in Fig. 1 with a KpnI site and
a base pair deletion engineered at the ATG translational start codon of orf118.
The plasmid was then digested with EcoRI and EcoRV, and the purified 900-bp
fragment was cloned in EcoRI-SmaI-digested pTCVlac to obtain pAtxA18.
In order to ensure that orf118 was no longer translated in this construct, a
translational lacZ fusion construct was generated by cloning a PCR fragment
obtained with oligonucleotide primers P1185?Eco and Ba1185?Sal in pJM115
digested with EcoRI and SalI. This resulted in fusion of the orf118 open reading
frame with the lacZ open reading frame at its internal SalI site. A ?-galactosidase
assay carried out with a B. subtilis strain transformed with this construct resulted
in essentially no activity, confirming that orf118 was not translated (data not
shown) after mutagenesis.
Every construct was fully sequenced to ensure fidelity of the PCR amplification.
mRNA purification, primer extension, and reverse transcriptase PCR (RT-
PCR). mRNA was purified essentially by the method described by Farrell in 1996
(12a). B. anthracis cells were grown in LB medium in air and in R medium in a
5% CO2atmosphere with 0.8% sodium bicarbonate to optical densities at 525
nm of 1.0 and ?0.4, respectively. Cells were collected by rapid filtration with a
0.22-?m Corning cellulose acetate filter system. The membrane with the cells was
washed immediately with liquid nitrogen, and the cells were collected in a conical
tube and stored at ?80°C. The cells were poured into a mortar containing dry ice
and broken by grinding with a pestle. Lysis was checked by phase-contrast
microscopy. The lysate was resuspended in extraction buffer (4 M guanidinium
thiocyanate, 25 mM sodium citrate, 0.5% sarcosyl, 100 mM ?-mercaptoethanol;
citrate buffer was added to 1? final concentration from a 10? concentrate at pH
7). The sample was vortexed until the powder was evenly dispensed in the buffer.
Then 0.1 volume of 3 M sodium acetate (pH 5.5) was added. Cell debris was
removed by centrifugation at 12,000 ? g for 10 min at 4°C. The supernatant was
recovered and extracted once with an equal volume of phenol-chloroform (1:1)
(pH 4.5). After centrifugation for 10 min at 4°C, the upper phase was recovered,
and the RNA was precipitated with 0.75 volume of cold isopropanol. After 1 h
of incubation at ?20°C, the sample was centrifuged for 20 min at 4°C, and the
pellet was washed with 70% cold ethanol and then resuspended in extraction
buffer in order to repeat the phenol-chloroform extraction and isopropanol
precipitation procedure one more time as described above. After the final cen-
trifugation and removal of the 70% ethanol, the pellet was resuspended in H2O
and stored at ?80°C. The concentration of mRNA was determined by spectro-
photometric analysis and by using a denaturing 1% formaldehyde gel (29).
In order to carry out the primer extension reaction, the oligonucleotide prim-
ers were labeled with [?-32P]ATP (4,500 Ci/mmol; MP Biomedicals) using T4
polynucleotide kinase (New England Biolabs) by following the supplier’s recom-
mendations. The primer extension reactions were carried out in 40-?l mixtures
containing approximately 60 ?g of mRNA and 1 ?M labeled oligonucleotide.
The reaction mixtures contained 1 ?l of RNase inhibitor (Perkin Elmer), each
deoxynucleoside triphosphate at a concentration of 0.5 mM, 5 ?M dithiothreitol,
1.5 ?l of Superscript III RT (Invitrogen), and 1? Superscript III RT reaction
buffer. The mixtures were incubated for 1 h at 48°C, and the reactions were
stopped with 5? formamide loading dye (95% formamide, 0.01% bromophenol
blue, 0.01% xylene cyanole). The mixtures were run on 5% acrylamide-8 M urea
gels using Tris-borate-EDTA buffer (29). The gels were dried and exposed to
PhosphorImager plates. The 1 Kb Plus molecular weight marker (New England
Biolabs) was also labeled by using [?-32P]ATP and polynucleotide kinase (New
The RT-PCRs were carried out with mRNA that was treated with RNase-free
DNase. Each extension reaction was performed with a 50-?l mixture that con-
tained 50 ?g of mRNA, 4.5 pmol of oligonucleotide primer AtxART2, each
deoxynucleoside triphosphate at a concentration of 0.5 mM, 5 mM dithiothreitol,
1? reaction buffer, and 0.5 ?l of Superscript III RT (Invitrogen). After 1.5 h of
incubation at 47°C, 5 ?l of each reaction mixture was used for PCR amplification,
using a 50-?l (final volume) mixture containing the AtxART3 and AtxART2 or
AtxA5?upEcoRI and AtxART2 oligonucleotides. Five microliters of each reac-
tion mixture was then analyzed by 1% agarose gel electrophoresis. The PCR
control reaction was an extension reaction performed with a mixture that did not
contain the Superscript III enzyme.
Sequencing reactions. Each sequencing reaction was carried out with a Se-
quenase DNA sequencing kit (USB) and ?-35S-labeled dATP (1,250 Ci/mmol;
MP Biomedicals), using oligonucleotide AtxART4 as the primer. The sequenc-
ing and primer extension reaction mixtures were run on a 5% acrylamide-8 M
urea sequencing gel with Tris-borate-EDTA buffer. The gel was dried and ex-
posed to a PhosphorImager plate.
?-Galactosidase assays. Cultures used for ?-galactosidase assays were grown
in 100 ml of LB medium in air or in R medium containing 0.8% sodium
bicarbonate in a an atmosphere containing 5% CO2. Duplicate samples were
removed at hourly intervals and processed essentially as previously described,
except that they were incubated with lysozyme for 1 h at 37°C and Triton X-100
was used at a final concentration of 0.5% (13).
Western blot analysis. Samples used for Western blot analysis of protective
antigen in culture supernatants, as shown in Fig. 2, were prepared as previously
described (31). Cells were grown in LB medium supplemented with erythromycin
and lincomycin, and supernatants were collected when the optical density at 525
nm of the cells reached 5.0 (which corresponded to approximately 3 h after the
transition to the stationary phase). The lanes contained volumes of supernatant
equivalent to the same cell optical density for all strains. The purified PA protein
used as control was purified from a Bacillus megaterium overexpression system
(MoBiTech Molecular Biotechnology, unpublished data).
Samples for the Western blot analysis shown in Fig. 7 were collected from
cultures grown in R medium with CO2/bicarbonate. Samples were collected at
the mid-exponential phase, at the transition phase, and 3 h into the stationary
phase. For PA analysis, 10 ?l of culture supernatant was run on a 12% sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis gel. For analysis of
AtxA, AbrB, and SigH, cells were collected by centrifugation, resuspended in 0.1
volume of water containing 5 mg/ml lysozyme and 50 U/ml mutanolysin, and
incubated at room temperature for 30 min. EDTA was added to a final concen-
tration of 0.1 M, and protease inhibitor (Roche) was added according to the
recommendations of the supplier. Samples were sonicated five times for 10 s
each time. Samples were mixed with SDS loading dye and run on 12% (AtxA and
SigH) or 16% (AbrB) SDS-polyacrylamide gel electrophoresis gels. Protein was
detected with an enhanced chemiluminescent light-based kit from Amersham
using a polyclonal antibody.
The production of the AtxA antibody was described by Tsvetanova et al. (31).
The B. subtilis AbrB protein and the B. anthracis SigH protein were used to
immunize rabbits using a standard protocol.
Deletion of the pXO1-118 gene reduces expression of the PA
gene. The pXO1-118 gene is 357 bp upstream of the atxA gene
and is transcribed divergently from it (Fig. 1). The pXO1-118
VOL. 190, 2008TRANSCRIPTION REGULATION OF AtxA6485
gene encodes a virulence plasmid sensor domain with a high
level of similarity to the sensor domain of the BA2291 sporu-
lation histidine kinase (5, 34). Both the pXO1-118 protein and
its paralogue encoded on the pXO2 virulence plasmid, the
pXO2-61 protein, were shown to inhibit the activity of the
BA2291 kinase and thereby inhibit sporulation initiation in B.
anthracis. A deletion of the pXO1-118 gene was generated by
replacing the entire coding sequence with a spectinomycin
resistance cassette, resulting in strain 34F2?118. While analyz-
ing the role of the pXO1-118 gene in the physiology of B.
anthracis, we found that deletion of this gene resulted in a 50%
decrease in pagA expression (Fig. 2A), as measured by a lacZ
reporter fusion, and a corresponding reduction in the level of
PA in the culture supernatant (Fig. 2B, compare lanes 1 and 3).
In order to test whether this effect was due to the absence of
the pXO1-118 protein, we constructed the in trans comple-
menting plasmid pAtxA3 in the pHT315 replicative plasmid
carrying the pXO1-118 gene coding sequence and 371 bp of
the pXO1-118 gene-atxA intergenic sequence (Fig. 1) (2).
Quantitation of PA expression in culture supernatants of the
parental strain and strain 34F2?118 carrying plasmid pAtxA3
revealed no restoration of PA production in the mutant com-
pared to the parental strain (Fig. 2B, compare lanes 2 and 4).
These results indicated that the pXO1-118 DNA in cis, but not
its gene product or the DNA in trans, was required for full
expression of pagA.
Full expression of atxA requires the DNA region containing
the pXO1-118 gene. Because the expression of pagA was re-
duced by deletion of the pXO1-118 coding sequence but not by
the absence of the pXO1-118 protein, we reasoned that dele-
tion of this DNA region could have affected the expression of
atxA, whose product is required for pagA expression. Thus, we
constructed an atxA-lacZ transcriptional fusion in vector
pTCVlac (pAtxA10) and tested the level of atxA transcription
in the 34F2?118 strain. The fragment in pAtxA10 contains the
P1 promoter previously identified as the atxA promoter (Fig. 1)
(9). The results (data not shown) did not reveal any difference
in the level of transcription between the parental 34F2 strain
and the pXO1-118 gene mutant strain. Therefore, we consid-
ered the possibility that DNA regions upstream of the frag-
ment cloned in pAtxA10 and encompassing the pXO1-118
gene could be involved in atxA transcription.
To examine this, a series of atxA-lacZ fusion plasmids were
constructed that contained fragments extending upstream of
atxA to include the entire pXO1-118-atxA intergenic region
(pAtxA13), the intergenic region and part of the pXO1-118
gene (pAtxA15), and the entire intergenic region and the
pXO1-118 gene region, including the putative rho-independent
terminator that follows it (pAtxA12). When ?-galactosidase
assays were carried out with the 34F2 strains carrying these
atxA-lacZ fusion constructs grown in LB medium (Fig. 3A), it
was observed that the fusion carrying the entire pXO1-118
gene, pAtxA12, had atxA transcriptional activity that was ap-
proximately threefold higher than that of the pAtxA10 fusion.
Using the pAtxA13 and pAtxA15 fusions, which contained the
intergenic region without and with a portion of the pXO1-118
FIG. 2. PA expression in the pXO1-118 gene deletion strain. (A) ?-
Galactosidase assay of the pagA-lacZ reporter in parental strain 34F2
(F) and in the 34F2?118 mutant strain (Œ). Cells were grown in LB
medium containing kanamycin. Time zero is the time of transition
between logarithmic growth and the stationary phase. (B) Western blot
analysis of the PA levels in culture supernatants of parental and
34F2?118 mutant strains complemented with the pXO1-118 gene on
the multicopy vector pHT315. Samples were collected at the time point
indicated by the double arrow in panel A. Lane 1, 34F2/pHT315; lane
2, 34F2/pAtxA3; lane 3, 34F2?118/pHT315; lane 4, 34F2?118/pAtxA3;
lane 5, purified PA (0.01 ?g). Lane M contained Western blot standard
Magic Mark XP (Invitrogen). The molecular masses of bands (in kDa)
are indicated on the left. The bands were quantitated with the Image
Quant software (Amersham-Molecular Dynamics), and the pixel value
for each lane is indicated below the gel.
FIG. 3. Transcriptional analysis of atxA-lacZ fusion constructs in
parental strain 34F2. Cultures used for ?-galactosidase assays were
grown in LB medium, and samples were taken at hourly intervals
before and after the transition (time zero) from exponential phase to
stationary phase. Symbols: ?, pTCVlac; ?, pAtxA10; ?, pAtxA12; E,
pAtxA13; ƒ, pAtxA15; f, pAtxA18; }, pAtxA19; Œ, pAtxA20; F,
pAtxA21; ‚, growth curve for a representative strain (34F2/pAtxA15).
OD525, optical density at 525 nm.
6486BONGIORNI ET AL. J. BACTERIOL.
gene, respectively, resulted in a level of atxA transcription that
was intermediate between that of the fusion with the short
fragment (pAtxA10) and that of the fusion with the long frag-
ment (pAtxA12) (Fig. 3A). Similar patterns of transcription
were observed when cells were grown in R medium with CO2/
bicarbonate, but significantly smaller differences in the level of
activity were observed between the pAtxA12 construct and the
pAtxA10 construct (see Fig. 7B and data not shown).
The levels of AtxA expression observed with each fusion
construct (pAtxA10, pAtxA12, pAtxA13, and pAtxA15) were
identical in the parental 34F2 strain and the 34F2?118 strain
(data not shown), confirming the lack of a role for the pXO1-
118 gene product in controlling atxA transcription. Transcrip-
tion from the pAtxA10 and pAtxA12 constructs was also not
affected by deletion of atxA itself (strain 34F2?atxA) (see Fig.
S1A in the supplemental material), ruling out the possibility of
an autoregulatory mechanism. Furthermore, the level of ?-ga-
lactosidase activity measured in the 34F2 strain carrying plas-
mid pAtxA22, which contained the long fragment but in which
the pXO1-118 gene was replaced by the spectinomycin resis-
tance cassette, was twofold lower than the activity measured in
the strain carrying the pAtxA12 construct (data not shown).
The findings just described again suggested that the DNA
containing the pXO1-118 gene was required for full atxA tran-
scription. In order to confirm this, an additional atxA-lacZ
fusion construct was generated in pTCVlac carrying the long
fragment like pAtxA12 but with the start codon of the pXO1-
118 gene replaced by the GTA sequence in a KpnI restriction
site and a base pair deletion that shifted the translational
frame (see Materials and Methods). ?-Galactosidase assays
carried out with the 34F2 strain containing the resulting plas-
mid, pAtxA18 (Fig. 1), showed that the translational frameshift
mutation in the pXO1-118 gene, which eliminated expression
of the pXO1-118 protein, did not affect the level of transcrip-
tion of atxA, which remained identical to the level obtained
with plasmid pAtxA12 (Fig. 3B).
Altogether, these results indicated that full transcription of
atxA requires the ?900-bp fragment upstream of its translation
start codon, which contains the divergently transcribed pXO1-
The atxA 900-bp upstream region contains an additional
promoter. In order to distinguish whether the 900-bp sequence
upstream of atxA was required for full expression because it
contained a binding site for an activator or contained an ad-
ditional promoter(s), two more atxA-lacZ fusions were gener-
ated with the same 5? end of pAtxA12 but with truncation at
the 3? end (Fig. 1); plasmid pAtxA19 lacked approximately 170
bp at the 3? end and the P1 promoter was deleted, while in
pAtxA20 the entire pXO1-118-atxA intergenic region was de-
leted. A third plasmid, pAtxA21, was also constructed and
contained the intergenic region without the P1 promoter.
?-Galactosidase assays carried out with the 34F2 strains con-
taining these plasmids in LB medium showed that the tran-
scription generated from the pAtxA21 reporter was not signif-
icantly different from the transcription observed with the
control vector pTCVlac alone, indicating that this fragment is
unlikely to carry an active promoter (Fig. 3A). In contrast,
efficient transcription was observed with the pAtxA19 and
pAtxA20 constructs, suggesting that promoter activity inde-
pendent of the P1 promoter was present. The transcription of
atxA from the pAtxA19 and pAtxA20 constructs initiated at the
same time during growth, as observed with the pAtxA10 and
pAtxA12 constructs but with different rates. The initial rate of
transcription was only 20% lower for pAtxA19 than for
pAtxA12, but it was 80% lower for pAtxA20 than for pAtxA12.
After 4 h of growth, the level of transcription from the frag-
ment in pAtxA19 was approximately the same as the level
obtained with the long fragment in pAtxA12, while the level of
transcription from pAtxA20 was approximately the same as the
level of transcription from the short fragment in pAtxA10. The
same pattern of gene expression was observed for all constructs
when cells were grown in R medium under CO2/bicarbonate
conditions (data not shown).
Altogether, these results suggest that the 900-bp region up-
stream of the atxA gene, which includes the pXO1-118 gene,
most likely contains an additional promoter for atxA expres-
sion. Furthermore, the pAtxA21 results indicate that this pu-
tative promoter is in the pXO1-118 gene coding region and not
in the intergenic region between the pXO1-118 gene and atxA.
The atxA transcript starts within the pXO1-118 gene. In
order to confirm that an atxA mRNA transcript initiated within
the sequence of the pXO1-118 gene, RT-PCRs were carried
out with DNase-treated mRNA from strain 34F2 grown in LB
medium using primer AtxART2 in the RT reaction and
the oligonucleotide primer pairs AtxART2-AtxART3 and
AtxART2-AtxA5?upEcoRI for PCR amplification (Fig. 1).
The results shown in Fig. 4 indicated that an amplified product
was obtained with the AtxART3 primer, located within the
pXO1-118 gene, but not with primer AtxA5?upEcoRI, which is
located upstream of the putative terminator that follows the
These results confirmed that atxA mRNA extended into the
pXO1-118 gene region and supported the hypothesis that there
was a promoter within the gene that contributed to atxA
transcription in addition to the P1 promoter identified by
Dai et al. (9).
FIG. 4. RT-PCR analysis of the atxA mRNA. RT-PCR was carried
out with mRNA extracted from strain 34F2 and treated with RNase-
free DNase. The mRNA was first incubated with (?) or without (?)
RT and oligonucleotide primer AtxART2 (RT2 in Fig. 1). An aliquot
of the reaction mixture was then incubated with oligonucleotide prim-
ers AtxART2 and AtxART3 (RT3 in Fig. 1) (lanes 1 and 2) or oligo-
nucleotide primers AtxART2 and AtxA5?upEcoRI (5?up in Fig. 1)
(lanes 4 and 5). Lanes 3 and 6 contained the products of PCR ampli-
fications carried out with oligonucleotides AtxART2 and AtxART3
and with oligonucleotides AtxART2 and AtxA5?upEcoRI, respec-
tively, using 34F2 genomic DNA as the template. Lane M contained
the 1 Kb Plus DNA ladder (New England Biolabs). Molecular sizes (in
base pairs) are indicated on the right.
VOL. 190, 2008TRANSCRIPTION REGULATION OF AtxA6487